Bioventus Inc.

For the period ended Mar 28, 2026. Filed May 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 28, 2026 · Filed May 6, 2026

BVS$11.18+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Condensed Balance Sheets as of and

Consolidated Condensed Balance Sheets as of March 28, 2026 and December 31, 2025

	March 28, 2026	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$35,846	$51,238
Accounts receivable, net	120,525	128,303
Inventory	83,187	82,236
Prepaid and other current assets	10,255	11,065
Total current assets	249,813	272,842
Property and equipment, net	21,294	21,899
Goodwill	7,462	7,462
Intangible assets, net	359,659	368,419
Operating lease assets	4,687	5,122
Deferred tax assets	5,522	5,522
Investment and other assets	2,102	2,293
Total assets	$650,539	$683,559
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$24,050	$10,928
Accrued liabilities	101,135	130,242
Current portion of long-term debt	18,750	15,000
Other current liabilities	4,160	4,210
Total current liabilities	148,095	160,380
Long-term debt, less current portion	253,326	278,951
Deferred income tax liabilities	568	433
Other long-term liabilities	14,285	15,348
Total liabilities	416,274	455,112
Commitments and contingencies (Note 11)
Stockholders’ Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued
Class A common stock, $0.001 par value, 250,000,000 shares authorized as of March 28, 2026 and December 31, 2025, 67,639,073 and 67,097,716 shares issued and outstanding as of March 28, 2026 and December 31, 2025, respectively	68	67
Class B common stock, $0.001 par value, 50,000,000 shares authorized, 15,786,737 shares issued and outstanding as of March 28, 2026 and December 31, 2025	16	16
Additional paid-in capital	522,912	520,851
Accumulated deficit	(331,816)	(334,929)
Accumulated other comprehensive loss	(2,279)	(1,900)
Total stockholders’ equity attributable to Bioventus Inc.	188,901	184,105
Noncontrolling interest	45,364	44,342
Total stockholders’ equity	234,265	228,447
Total liabilities and stockholders’ equity	$650,539	$683,559

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.